Fibrocalculous pancreatic diabetes by Mohan, V. & Premalatha, G.
Fibrocalculous Pancreatic Diabetes 
V. Mohan and G. Premalatha 
M.V. Diabetes Specialities Centre, 44 Royapettah High Road, Madras - 600 014, India 
 
1. Introduction 
In developing countries, peculiar forms of diabetes associated with undernutrition have 
been reported since the beginning of the century. Conflicting criteria and varied clinical 
presentations of the disease led to confusion in proper characterization of these forms of 
diabetes. In 1985, thanks largely to the work of Bajaj1, the WHO study group report on 
diabetes2 included Malnutrition Related Diabetes Mellitus (MRDM) as a form of diabetes 
distinct from Insulin Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent 
Diabetes Mellitus (NIDDM). Under MRDM two subgroups are recognized: 
Fibrocalculous Pancreatic Diabetes (FCPD) and Protein Deficient Diabetes Mellitus 
(PDDM). FCPD is a type of diabetes secondary to a unique form of chronic pancreatitis 
seen in developing countries. PDDM is distinguished from IDDM in that despite severe 
insulin requiring diabetes, patients do not develop ketosis if insulin injections are 
withdrawn. This article will only deal with FCPD. 
2. Terminology 
Several terms have been proposed for this syndrome including Tropical Calcific 
Pancreatitis, Tropical Chronic Pancreatit-is, Tropical Pancreatic Diabetes, Nutri-tional 
Pancreatitis, Endemic Pancreatic Syndrome etc. For sake of uniformity and international 
agreement in description of the disease it is advisable to adopt the WHO study group 
report term - Fibrocalculous Pancreatic Diabetes (FCPD). We and several other groups 
had earlier used the term ‘tropical’ to describe this disease. However, due to migration of 
patients from tropical to temperate zones, the disease is occasionally reported from 
developed countries3,4 in migrants from tropical countries. Hence the term ‘tropical’ is 
best avoided. We propose that the term Fibrocalculous Pancreatitis (FCP) be used when 
one refers to the pancreatitis and Fibrocalculous Pancreatic Diabetes (FCPD) when one 
refers to the diabetes secondary to FCP. 
FCP differs from alcoholic chronic pancreatitis seen in the western world in several 
respects: the age at onset is younger, the disease has a more accelerated course, the 
prevalence of diabetes and pancreatic calculi is considerably higher and finally 
alcoholism is absent (by definition). The differences between FCP and alcoholic chronic 
pancreatitis have been reported by us earlier5,6 and they are summarized in Table 1. 
3. Historical background & prevalence 
In 1959, Zuidema7 from Indonesia was the first to describe diabetes associated with 
pancreatic calculi and protein calorie malnutrition. Reports from several tropical parts of 
the world including Uganda, Nigeria, Brazil and several countries in Asia including 
Thailand, Bangladesh and Sri Lanka subsequently confirmed the existence of this 
syndrome.8-12 In India the frequency of FCPD is higher in the South than the North. 
Geevarghese9 one of the pioneers in the field has reported on over 1700 cases from the 
state of Kerala in south western India which in fact has the highest known prevalence of 
FCPD in the world. Large series have also been reported from Kerala10, Tamil Nadu11,12, 
Orissa13, Karnataka14 and other parts of India. 
In Kerala, in the 1960’s, FCPD constituted 29.3% of the total diabetic cases admitted as 
inpatients at the Kottayam Medical College9. However, this figure came down to 0.009% 
in 1980. This might however reflect a change in priorities for admission to the hospital as 
most diabetic patients would now be treated on an out-patient basis. There is only one 
population based study on the prevalence of fibrocalculous pancreatitis. Balaji15 made a 
systematic survey of 6079 families in Quilon district, Kerala. A population of 28,507 was 
studied by clinical history, ultra-sonography and Para-amino-benzoic acid (PABA) tests. 
Twenty-eight cases (1:1000) had chronic calcific pancreatitis. At the M.V.Diabetes 
Specialities Centre (MVDSC) at Madras, a large referral centre for diabetes, about 50 
patients with FCPD are registered annually which constitutes 1% of all diabetics and 4% 
of "young" diabetics (defined as onset below 30 years of age) seen at our centre. Figure 1 
shows the distribution of FCPD in relation to other types of diabetes seen at MVDSC, 
Madras. 
For the last few years a " pancreatitis " registry has been set up at our centre. The current 
status of patients in this registry is shown in Table 2. It can be seen that FCPD and Pre-
FCPD together comprise 393/484 patients (81.2%) of chronic pancreatitis. Thus FCP is 
the commonest form of chronic pancreatitis seen at our centre and Alcoholic Chronic 
Pancreatitis is the next common type (16.7%). 
4. Clinical features 
FCPD patients present with several distinct clinical features. Patients are invariably poor 
and present with extreme emaciation, protein energy malnutrition, bilateral parotid 
enlargement, distension of the abdomen and rarely, a cyanotic hue of the lips. Recently 
there appears to be a change in the clinical features of FCPD patients because of 
improved nutritional status. In our series16 overt malnutrition was observed only in 25% 
of patients, although 70% were lean. Many FCPD patients are from the middle and a few 
from the upper strata of society. While leanness continues to be a feature, extreme 
degrees of undernutrition and emaciation are less common. A body mass index (BMI) of 
less than 19, often taken as a criterion for undernutrition, is seen in about 50% of our 
patients while the rest have BMI varying from 19-25. In the majority of patients the 
diagnosis of diabetes is made between the ages of 20 and 40, but onset in childhood17, in 
infancy18 and in older age groups19 is not uncommon. 
5. Natural History of FCPD 
The cardinal triad of FCPD is abdominal pain, pancreatic calculi and diabetes. 
In the natural history of FCPD the first symptom to manifest is usually abdominal pain. 
After periods varying from a few months to several decades, pancreatic calculi may be 
diagnosed by routine abdominal radiography. At this time the patient may still have 
normal glucose tolerance and no evidence of exocrine pancreatic dysfunction. After some 
months to years, glucose intolerance and/or exocrine pancreatic dysfunction may set in as 
shown in Fig 2. 
Although this is the classical natural history, sometimes the first sign of the disease may 
be pancreatic calculi, diabetes or steatorrhoea 
5a. Pain Abdomen 
FCPD patients usually have a history of recurrent abdominal pain from childhood. 
However, we19 have seen that in the older cases (above 60 years) the pain may start in the 
4th or 5th decade of life. It is usually very severe, epigastric in location, may radiate to 
the back and is relieved by stooping forward or lying in a prone position. It is 
characterized by periods of remission and exacerbation and usually abates by the time 
diabetes sets in. Hence the frequency of pain is always higher in a gastroenterologist’s 
series than in a diabetologist’s series. Due to the intensity of the pain, many patients 
become addicted to powerful narcotic analgesic drugs. 
5b. Steatorrhoea 
Overt steatorrhoea is seen in about a third of patients. However in others it may be 
subclinical and is diagnosed by exocrine pancreatic function tests. The low frequency of 
steatorrhoea is attributed to the low fat content of the diet. When the fat content of the 
diet was experimentally increased, steatorrhoea was found to occur in over 90% of 
patients.10 
5c. Nature of Diabetes 
Diabetes is usually severe and occurs a decade or two after the first episode of abdominal 
pain. Despite requiring insulin for control of hyperglycaemia, FCPD patients rarely 
develop ketoacidosis on withdrawal of insulin. This may be due to several factors. Our 
studies21 as well as that of others20,22-24 have shown that the pancreatic beta cell function 
is partly preserved in patients with FCPD. This residual b -cell reserve may be sufficient 
to protect against ketoacidosis. Other explanations for the resistance to ketosis include: a 
low glucagon reserve, decreased adipose tissue mass and carnitine deficiency.20 
Contrary to earlier reports, insulin requirement is not very high and the mean daily 
insulin dose in our patients is 40± 12 units especially if sulphonylureas are also used. The 
latter are in fact often combined with insulins as they help to reduce the cost of treatment 
as insulin is expensive. Thus insulin resistance is not a feature of FCPD. On the contrary 
many patients may be sensitive to insulin and hypoglycaemia may occur more often. This 
could be explained by the absence of glucagon. 
We11 have shown that there is a wide spectrum with respect to the clinical severity of 
FCPD. While most patients require insulin injections, about 10-20% of patients may 
respond to oral hypoglycaemic agents at least for the first 5-10 years and in some cases 
for much longer periods of time. While the majority of the insulin requiring patients are 
ketosis resistant, a few may be prone to ketosis. The response to therapy appears to 
correlate with the pancreatic b -cell function, as assessed by serum C-peptide levels.15,16 
Although most patients ultimately develop overt diabetes, we have seen patients in the 
stage of Impaired Glucose Tolerance (IGT) and at a still earlier stage, the glucose 
tolerance can be normal. We propose that the terms Pre-FCPD be used to denote the stage 
of Normal Glucose Tolerance, FCP-IGT to denote the IGT phase and FCPD after overt 
diabetes has set in. 
6. Radiological features 
Presence of pancreatic calculi is the hallmark of FCPD. The calculi are multiple, large, 
rounded, dense, discrete and always confined to larger ducts. They are usually seen to the 
right of the first or second lumbar vertebrae, but may occasionally overlap the spine. In 
some patients the whole pancreas may be studded with calculi. We6 and Geevarghese9 
have shown that in FCPD, unlike in Alcoholic Pancreatitis, calculi are very rarely seen to 
the left of verterbrae i.e. in the tail region of the pancreas, as they tend to start in the 
larger ducts, i.e. in the head region and then proceed tailward. The opposite appears to be 
the case in alcoholic pancreatitis. 
Ultrasound and CT scan help to confirm the location of calculi within the pancreatic duct 
and to document other features of chronic pancreatitis, e.g. ductal dilatation. They also 
provide information regarding the structural changes in the gland particularly the ductal 
morphology. Ultrasound findings reported by us25 include shrinkage in size of the gland, 
increased echogenicity and ductal dilatation which is often very marked. CT scaning has 
allowed a closer look at pancreatic morphology during life20. The pancreatic mass is 
preserved in the " early " stages and swelling of the parenchyma is evident. In more 
advanced stages, the pancreas shows varying degrees of atrophy and finally there may be 
very little pancreatic parenchyma, its place being taken by a "bag of stones". In some 
cases, fat infiltration is prominent. The pancreatic duct appears irregularly dilated with 
stones in the lumen. 
Endoscopic retrograde cholangio- pancreatography (ERCP) is rarely required to diagnose 
FCPD. However it is sometimes useful to diagnose "non calcific FCPD" where the ductal 
abnormalities help to diagnose this condition26. 
7. Pathology 
The pathology of the pancreas in FCPD has been described in detail by Nagalotimath.27 
Macroscopically the pancreas of FCPD patients is usually small, atrophic and fibrosed. 
The ducts are dilated with multiple calculi in the major ducts or its tributaries. Mucinous, 
putty - like material which are protein plugs, form the initial nidus on which calcium 
deposition takes place. The calculi are composed of carbonates, with traces of 
phosphates, oxalates, magnesium and proteins. 
Studies on the histopathology of the pancreas have been based on biopsy or autopsy 
specimens. In most studies patients with advanced stages of the disease have been 
studied. Excellent reviews by Nagalotimath27 and Nair28 have described the pathological 
lesions in FCPD. 
In the initial stages, inflammatory changes may be seen in the exocrine pancreas. These 
consist of infiltration by lymphocytes, plasma cells and eosinophilic cells. As the disease 
progresses, widespread destruction of acini occur and inflammatory cells may not be 
seen. 
Fibrosis starts early and classically leads to "cirrhosis of the pancreas". In some cases, 
extensive fat infiltration also occurs. Ducts and ductules show degenerative changes, and 
the lining epithelium may show squamous cell metaplasia. Ductules crowd together due 
to loss of intervening acinar tissue and also show true proliferation. In some patients 
pathological changes suggest "localised and arrested" disease27. 
The islets of Langerhans appear to be intact till fairly advanced stages of the disease. 
There is no "insulitis". Hypertrophy as well as atrophy are seen. Nesidioblastosis is a well 
described feature. The islets are probably destroyed later due to surrounding fibrosis 
(‘strangulation’), and possibly also by disruption of blood supply. There are no studies of 
islet numbers in FCPD but presumably they must be severely diminished with 
progression of the disease. 
8. Exocrine pancreatic function 
Several authors have reported on exocrine pancreatic function in FCP. Punnose et al29 
reported the usefulness of the Lundh Meal test. Using a cut-off point of 21 u/ml, 93% of 
the calcific FCP cases compared with 27% of the non-calcific variety had low tryptic 
activity. 
Secretin-pancreozymin tests done by Balakrishnan’s group30 in collaboration with the 
Marseille group showed that the lactoferrin level of the pancreatic juice was considerably 
higher in Indian patients and controls than in their European counterparts. This suggests 
that the pancreatic acinar cells could be hyperactive, perhaps in response to a pancreatic 
insult. 
Serum immunoreactive trypsin measurements showed a spectrum of exocrine pancreatic 
involvement.31-34 In early cases (normal glucose tolerance and IGT) serum 
immunoreactive trypsin was subnormal only in a few subjects, while in some it was 
markedly elevated suggesting active pancreatitis. The exocrine reserve appeared 
relatively well preserved till a late stage. In advanced cases (FCPD), serum 
immunoreactive trypsin was subnormal in most cases and severely diminished in over 
two thirds. Faecal chymotrypsin measurements showed similar results31,33 as did 
pancreatic isoamylase.31,34 In our experience faecal chymotrypsin test is a simple and 
inexpensive method for screening for exocrine pancreatic insufficiency in FCPD patients. 
9. Variability of FCP 
Recent studies mentioned above highlight the variable nature of the FCP. 
Table 3 summarizes the variability with respect to the clinical, biochemical, ERCP and 
histopathological features of FCP. 
10. Criteria for FCPD 
Despite excellent clinical descriptions of the disease, no definite criteria have been laid 
down as yet for the diagnosis of FCPD. Mohan et al8,11 have proposed the following 
criteria for the diagnosis of FCPD, based on their own studies and an extensive review of 
the literature (Table 4). 
11. Specific diabetic complications 
It was earlier believed that being a secondary form of diabetes, microvascular 
complications are rarely seen in FCPD. Our studies16,35 and that of Geevarghese36 have 
shown that microangiopathy occurs as frequently in FCPD as in primary forms of 
diabetes like NIDDM and IDDM. We35 have shown that sight-threatening forms of 
retinopathy i.e. both maculopathy and proliferative retinopathy do occur in FCPD 
patients. Neuropathy, nephropathy and left ventricular dysfunction, also occur in our 
patients16. Recently Govindan and Das37 have reported on the occurrence of autonomic 
neuropathy in FCPD patients. 
In contrast, macrovascular complications were less common in FCPD, but we have seen 
occasional occurrence of ischaemic heart disease and peripheral vascular disease38. The 
low frequency of macrovascular complications may be due to the relative young age of 
the patients, leanness and the low cholesterol levels16. 
12. Complications due to chronic pancreatitis  
Complications due to chronic pancreatitis include pseudocysts, pancreatic abscess 
obstructive jaundice, which can either be due to stenosis of the common bile duct or a 
stone obstructing the passage or due to associated carcinoma of the pancreas. Recent 
studies from our group,39 Augustine40 and Balakrishnan10 suggest that FCPD could be a 
premalignant condition as several patients with FCPD were noted to develop carcinoma 
of the pancreas on follow-up. Current evidence39 suggests that the risk for developing 
carcinoma in FCP is higher than in temperate zone pancreatitis al-though the reasons for 
this are not clear. 
13. Management of chronic pancreatitis  
Pancreatic enzymes help to reduce steatorrhoea and may indeed, alleviate pancreatic pain 
in some cases. More often however, pain is severe and intractable and is not relieved 
even by powerful analgesics. At this stage, surgical intervention may benefit. 
Sphincterotomy, side-to-side pancreatico- jejunostomy (Puestow’s procedure) and end-
to-side pancreatico-jejunostomy (Duval’s procedure) have been tried. Many of these 
procedures are beneficial with respect to alleviation of pain. Some patients however have 
recurrence of pain and these procedures rarely alter the diabetic status of the patient. 
Tripathy and Samal41 reported that after surgery the mean daily insulin requirement fell 
from 46 units to 34 units and that the basal serum insulin improved from a mean of 4.3 to 
10.2 micro units/ml in patients. However it is likely that these changes are usually 
transient and the diabetic status appears to be largely unaffected by surgery. 
14. Aetiology and pathogenesis 
The etiopathogenic mechanisms for FCPD are still unclear. Malnutrition and cyanogenic 
alkaloids (derived from cassava or other food items) have often been incriminated as 
etiological factors. Recently, ‘oxidant stress’ has been proposed as a mechanism in 
pancreatic damage. 
14a. Malnutrition 
Severe clinical malnutrition at the time of diagnosis in several FCPD patients suggested 
to many workers a causative role for nutritional deficiencies.8,10,42-45 However, a past 
history of severe malnutrition (kwashiorkor) is usually absent. Moreover, malnutrition at 
presentation may well be secondary to severe exocrine and/or endocrine pancreatic 
deficiency. A proportion of FCPD patients do not show undernutrition by the BMI 
criteria.16,46 Recent work suggests that micronutrient deficiency rather than overt protein 
and calorie deprivation, may predispose to FCPD (see below). 
14b. Cyanogenic alkaloids 
McMillan and Geevarghese47 observed the geographical occurrence of FCP in areas 
where the tuber cassava (tapioca, manihot) is consumed as a staple food and suggested a 
causative role for cassava in the aetiology of this condition. They suggested that dietary 
deficiency of sulphur amino acids (methionine, cystine) could hamper detoxification of 
cyanide to thiocyanate and lead to high levels of ‘free’ cyanide which might be toxic to b 
-cells. Studies in rats have shown that cyanide administration can lead to transient 
hyperglycaemia but not to permanent diabetes.9,16 The relevance of these observations to 
the clinical situation is still unclear, especially the role of cyanide in causing pancreatic 
damage. Recent studies in Africa48 failed to find FCPD in areas where cassava is eaten as 
a staple food but this again could be related to differences in processing/cooking of the 
tuber. The role of other foodstuffs which may contain cyanogenic glycosides merits 
further study. 
14c. Genetic, familial and immunological factors 
Familial clustering of FCP, sometimes in successive generations has been 
described.10,36,49,50 In our series50 12% of parents and 21% of siblings of FCPD patients 
showed evidence of exocrine pancreatic involvement, and 21% of parents and 11% of 
siblings had previously undiagnosed NIDDM. In the absence of a specific genetic 
marker, it is difficult to say if these results reflect a genetic transmission or a shared 
environmental factor. We51 also recently reported that about 40% of FCPD patients 
shared the HLA-DQ-B haplotype which is usually associated with IDDM. Another 40% 
of FCPD patients showed an association with the class 3 allele of the insulin gene which 
is similar to the association seen in our NIDDM patients. Obviously more work is 
needed, but these studies provide evidence for the first time, for a genetic susceptibility to 
FCPD. 
14d. Oxidant stress and anti-oxidant deficiency 
Braganza52 has suggested that chronic pancreatitis in the U.K. is a result of heightened 
but unmitigated oxidative detoxification reactions in the pancreas and liver, coupled with 
exposure to xenobiotics biotransformed by cytochrome P-450 enzyme systems and a 
relative deficiency of anti-oxidants. She has now extended the hypothesis to include 
FCP53. In preliminary collaborative studies, we54 found evidence of increased exposure to 
xenobiotics, especially polycyclic aromatic hydrocarbons (cigarette, kerosene and 
firewood smoke and vehicular fumes) in patients of FCP compared to controls. This was 
associated with elevated theophylline clearance (a marker for heightened cytochrome P-
450 activity)55. 
Further studies56 have shown evidence of anti-oxidant deficiency, particularly of Vitamin 
C and Beta Carotene in the Madras FCP patients and control subjects compared to the 
Manchester subjects. The levels of selenium and Vitamin E were not significantly 
different between the two groups. More studies are needed on the micronutrient status of 
FCP patients to confirm these findings. 
Conclusion 
Fibrocalculous Pancreatitis is a unique form of chronic pancreatitis seen in developing 
countries associated with either overt protein calorie malnutrition or more likely with a 
deficiency of certain micronutrients. Compared to temperate zone pancreatitis, FCP 
affects younger individuals and has a more aggressive and accelerated course to reach the 
end points of diabetes, pancreatic calculi and exocrine pancreatic dysfunction. There are 
characteristic features of FCP radiologically, ultrasonographically, on ERCP and on 
histopathology. Although a secondary form of diabetes, specific diabetes related 
complications do occur in FCPD. There appears to be a high risk of developing 
pancreatic carcinoma. Although the etiology of FCPD is still unclear, the role of 
micronutrient deficiency merits further study. The contribution of genetic factors and 
environmental toxins e.g. cyanogenic glycosides still remains unclear.  
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